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Abstract Clinical gout has rarely been described after
pediatric renal transplantation (RTx), although asymptom-
atic hyperuricemia is common in these patients. We
describe three male pediatric patients who presented with
gouty arthritis 7–8.5 years following RTx. Since receiving
allopurinol, all patients had been free of gouty symptoms.
To prevent severe bone marrow depletion, the dosage of
azathioprine, an immunosupressant drug, was reduced by
50% to prevent interaction with allopurinol. Because
atypical presentation of gout can occur, a high index of
suspicion is needed to allow appropriate diagnosis of this
disease in patients with skeletal pain after RTx.
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Introduction
Hyperuricemia and gout are common problems among adult
renal transplant recipients [1, 2]. Gout is a painful disorder
caused by an inflammatory reaction to the presence of
monosodium urate crystals in the joint fluid and periarticular
tissue, which in turn is the result of longstanding hyperuri-
cemia [3]. In pediatric renal transplant recipients, asymp-
tomatic hyperuricemia occurs most frequently in those
patients who have survived a long time after transplantation,
and it is probably a consequence of chronic renal transplant
dysfunction [4]. Gout, however, is rare in these patients. We
report on three patients who presented with partly atypical
manifestation of gouty arthritis several years after
undergoing pediatric renal transplantation (RTx).
Patients
Three male patients were found to have gouty arthritis 7–
8.5 years following RTx. All patients had impaired renal
function due to chronic transplant nephropathy.
Patient A, a 15-year-old boy with sporadic steroid-
resistant focal segmental glomerulosclerosis, suffered from
clinical gout, with the first episode occurring 8 years after
RTx. The clinical manifestation was typical arthritis of the
metatarsophalangeal joint of the left big toe [4].
Patient B, a 17-year-old male adolescent with renal
hypodysplasia, presented with fever, chills, and painful
swelling localized above the head of the second metatarsal
bone 8.5 years after RTx. Following plain radiography and
magnetic resonance imaging (Fig. 1) of the right forefoot, he
underwent biopsy to exclude osteomyelitis or septic arthritis.
Blood culture as well as culture and eubacterial PCR of a
bone specimen yielded negative results. Histopathological
examination ultimately revealed gouty synovitis (Fig. 2).
Patient C, a 12-year-old boy with congenital nephrotic
syndrome of the Finnish type, showed a typical clinical
presentation with gouty arthritis of the metatarsophalangeal
joint of the left big toe 7 years after his second renal
transplantation (the first transplant was rejected 9 days after
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a living donor kidney transplantation at 2 years of age). The
most important clinical and laboratory findings as well as
the drug therapy are listed in Table 1. After receiving long-
term allopurinol (2–6 mg/kg/day), all patients were free of
gouty symptoms.
Discussion
Hyperuricemia and gout are frequent complications in adult
renal transplant recipients, with reported prevalences of up
to 80 and 10%, respectively [1, 2]. Immunosuppressive
agents, such as ciclosporin and tacrolimus, play a key role
in inducing hyperuricemia and gout [3]. Hyperuricemia also
seems to be common in pediatric patients. In one study,
elevated uric acid concentrations were found in 47% of the
pediatric patients after a median period of almost 5 years
post-transplantation [4]. Clinical gout, however, is rare in
these children [5]. We report here the history of three
patients with new-onset clinical gout. Our aim was to alert
physicians to the possibility of this rare clinical entity
presenting in pediatric patients after RTx.
In general, gout has a predilection for the first meta-
tarsophalangeal joint as well as wrists, knees, and elbows
[2]. Proximal distribution of gouty arthritis involving the
hips, shoulders, and sacroiliac joints as well as gouty
enthesitis have also been described [6]. Onset is abrupt, and
the affected joints are erythematous, warm, swollen, and
tender. Patients A and C presented with classical podagra,
characterized as an acute gouty arthritis of the first
metatarsophalangeal joint. Hyperuricemia was present in
both and supported the clinical diagnosis of gout. However,
in patients with more pronounced inflammatory manifes-
tations, gouty arthritis should be distinguished from septic
arthritis, and immunosuppressive therapy does not seem to
mitigate symptoms in all transplant patients [2]. This latter
observation is upheld in patient B, who presented with
fever, chills and less typical localization of joint involve-
Fig. 2 Microscopic aspects of
gouty tophus (Patient B). a
Clusters of eosinophilic urate
crystals (arrow) surrounded by
histiocytes and macrophages
[hematoxylin/eosin stain (HE),
10×]. b Higher magnification
presenting detritus and rare urate
crystals (arrow) inducing an
inflammation of the foreign type
(HE, 40×)
Fig. 1 a Plain radiograph of the
right forefoot (Patient B): area
of osteolysis (arrow) in the head
of the second metatarsal bone. b
Magnetic resonance imaging of
the right forefoot (Patient B):
edema of the soft tissue and of
the bone marrow (arrow) in the
diaphysis and the head of the
second metatarsal bone with
sclerotic destruction on the lat-
eral border; effusion in the sec-
ond metatarsophalangeal joint
with synovial enhancement
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ment. Therefore, this patient was further investigated to
search for infectious complications. Notably, gout and
septic arthritis can coexist within the same joint [7].
Pseudomonas aeruginosa was not present in patient B;
infection by this microorganism has been described in
patients as a complication following (unnoticed) puncture
wounds while wearing sneakers [8]. In this patient, gout
was finally diagnosed by histopathological examination of
biopsy specimens.
In the vast majority of patients with gouty arthritis,
hyperuricemia is a prerequisite, at least at some point in
their disease [3], although it is worth noting that some
patients do have normal uric acid concentrations during an
acute attack of gout [9]. Several factors may contribute to
the occurrence of hyperuricemia in renal transplant recip-
ients: (1) ciclosporin; (2) diuretics; (3) hypertensive
nephropathy [2], and (4) chronic renal transplant dysfunc-
tion [4]. In pediatric renal transplant recipients, however,
the hyperuricemic effect of ciclosporin appears to be less
relevant than in adults. In the former, plasma uric acid
concentration significantly and positively correlates with
the length of the time span after renal transplantation and
inversely correlates with renal function [4]. The impact of
impaired renal function on the development of hyperurice-
mia long after RTx and the subsequent existence of gout
was apparent in our three patients. Additionally, only one of
the present patients received diuretic treatment (Patient A).
The treatment of gout in transplant recipients is
challenging due to the potential for drug interactions and
the risk of side effects. The standard treatment of acute
attacks of gout consists of rest, application of ice to the
affected joint, and a prescription for colchicine, non-
steroidal anti-inflammatory drugs (if not precluded by
limited renal function), or both. Alternatively, and probably
more suitable in renal transplant recipients, a short-term
course of systemic corticosteroids (e.g. prednisolone 1 mg/
kg/day for 4–7 days) or intra-articular corticosteroid
injections are of great value in terms of improving the
symptoms [3]. Xanthine oxidase inhibitors, such as allopu-
rinol, are also a very effective treatment option, especially
as a prophylaxis of gout. Since the metabolism of
azathioprine is partly dependent on xanthine oxidase, co-
administration of these drugs results in an increased risk of
severe bone marrow toxicity. Therefore, some treatment
protocols avoid this combination [10]. If, however, azathi-
oprine and allopurinol are co-administered, the dose of the
former has to be reduced by approximately 50%, and
careful monitoring of blood cell counts is mandatory.
Alternatively, a switch from azathioprine to mycophenolate
mofetil can be considered, as this will avoid potential toxic
drug interactions. Further therapeutic options in these
patients are colchicine and uricosuric agents [11]. In our
patients, treatment with allopurinol and co-administration
of a reduced dose of azathioprine in two of them were
tolerated without signs of toxicity.
In conclusion, despite the common occurrence of
hyperuricemia in pediatric renal transplant recipients, gout
remains rare in these patients. Clinical gout usually occurs
several years after RTx, and presentation might be atypical.
Consequently, diagnosis can be challenging. Because of
possible drug interactions and the risk of side effects,
treatment should be individually managed by a pediatric
nephrologist.
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Table 1 Clinical, pharmacological and laboratory findings of the three patients
Patient data Patient A Patient B Patient C
Diagnosis FSGS RH CNS Finnish type
Age (years) 15 17 12
Time post RTx (years) 8 8.5 7
Affected joint MTP I MTP II MTP I
Plasma creatinine (μmol/l) 217 175 218
eGFR (ml/min/1.73 m2)a 29 39 29
Uric acid (μmol/l) 929 709 611
Immunosuppression CSA, AZA, PDN CSA, AZA SIR, MMF, PDN
Diuretics Furosemide - -
FSGS, Steroid-resistant focal segmental glomerulosclerosis; RH, renal hypodysplasia; CNS, Congenital nephrotic syndrome; RTx, renal
transplantation; eGFR, estimated glomerular filtration rate; MTP, metatarsophalangeal joint; CSA, ciclosporin A, SIR, sirolimus; AZA,
azathioprine; MMF, mycophenolate mofetil; PDN, prednisolone
a Determined by the Haycock-Schwartz formula
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